New Method Developed to Produce Modified Delta Sleep-Inducing Peptide
Background
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide known for its sleep-promoting effects and potential therapeutic applications in conditions like insomnia and stress-related disorders. However, its short half-life in the bloodstream and poor ability to cross cell membranes significantly limit its clinical utility. This study addresses the critical need for an efficient and high-yield method to produce a modified DSIP fusion protein with enhanced stability and cellular uptake, paving the way for more effective therapeutic development.
Study Design
Results
The study successfully demonstrated the high-level expression of the DSIP-PTD-HSA fusion protein in Pichia pastoris, confirming its identity with an expected molecular weight of approximately 70 kDa via SDS-PAGE and Western blot analysis. Optimized fermentation conditions, including specific methanol induction protocols, led to a significant increase in protein production, reaching an impressive yield of 250 mg/L of culture supernatant. The multi-step purification process achieved an exceptional degree of purity, with the final DSIP-PTD-HSA fusion protein exhibiting over 95% homogeneity, as determined by densitometry of SDS-PAGE gels. This optimized protocol resulted in a remarkable 3-fold increase in overall protein yield compared to initial unoptimized conditions, making large-scale production economically feasible. Furthermore, the purified protein maintained its structural integrity and antigenicity, suggesting its suitability for further functional studies.
Why It Matters
This research is highly significant because it establishes a robust, efficient, and scalable method for producing a modified Delta Sleep-Inducing Peptide (DSIP) with enhanced pharmacokinetic properties. The successful fusion with a Protein Transduction Domain (PTD) and Human Serum Albumin (HSA) directly addresses the critical limitations of native DSIP, potentially leading to improved therapeutic efficacy and extended duration of action in vivo. This efficient production method paves the way for preclinical and potentially clinical development of DSIP-PTD-HSA as a novel therapeutic agent for sleep disorders, neurological conditions, and stress management. Future work will focus on rigorously evaluating the biological activity, safety, and pharmacokinetics of this fusion protein in relevant animal models, with the ultimate goal of progressing towards human clinical trials.